drugset / Trial / NCT00961090

Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery

NCT00961090

NaSingle-groupOpen-labelTreatment

Summary

A one time oral dose of ALA is taken before surgery. The medication makes the tumor visible under ultraviolet light which allow the surgeon to see more of the tumor for a more complete removal.

Timeline

Start
2009-09
Primary completion
2015-04-22
Completion
2015-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminolevulinic Acid Diagnostic / imaging agent 20 mg/kg Oral

Indications